# US 7,005,502 B1 · Pharmaceutical preparation comprising vWF propeptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,005,502 B1
- Document ID: US7005502B1
- Status: Granted
- Kind: B1
- Application number: 09/424,498
- Filed: 1998-05-26
- Granted: 2006-02-28
- Earliest claimed: 1997-05-28
- Assignees: Baxter Aktiengesellschaft
- Inventors: Hans-Peter Schwarz; Katalin Varadi; Peter Turecek; Hendrik Coenraad Hemker; Suzette Lucette Beguin
- Web page: https://patentgrep.com/patent/US7005502B1

## CPC

- A61K 38/37: Factors VIII
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.

## Claims

### Claim 1

A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and a hemostasis protein, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

### Claim 2 (depends on 1)

A preparation as set forth in claim 1, wherein said hemostasis protein is a blood factor.

### Claim 3 (depends on 2)

A preparation as set forth in claim 2, wherein said blood factor is selected from the group consisting of mature vWF, factor VIII, activated blood coagulation factors, and blood factors with factor VIII inhibitor bypassing activity.

### Claim 4

A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and a phospholipid, wherein the preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

### Claim 5

A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and at least two components, wherein the components are selected from the group consisting of a blood factor, a platelet component, and a phospholipid, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.